Literature DB >> 11167841

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.

N Kröger1, W Krüger, H Renges, T Zabelina, N Stute, R Jung, G Wittkowsky, R Kuse, A Zander.   

Abstract

Two patients with persistent disease after allografting for multiple myeloma received donor T-cell lymphocyte infusion (DLI) (1.5 x 10(8) and 7 x 10(7)) to induce a graft-vs.-myeloma effect for further tumour regression after withdrawal of immunosuppression. The interval between stem cell transplantation and DLI was 8 and 14 months respectively. Both patients converted from partial to complete remission, lasting 12+ and 28+ months. Immunofixation became negative after 3 and 4 months. The main toxicity was grade II and III acute graft-vs.-host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma.

Entities:  

Mesh：

Year:  2001        PMID： 11167841     DOI： 10.1046/j.1365-2141.2001.02599.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  9 in total

1.  Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect".

Authors:  Stefan O Schonland; Nicolaus Kröger; Christine Wolschke; Peter Dreger; Anthony D Ho; Ute Hegenbart
Journal:  Haematologica       Date:  2009-01-27       Impact factor: 9.941

Review 2.  Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Authors:  B Dhakal; D H Vesole; P N Hari
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 3.  Current status of stem cell transplantation for multiple myeloma.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne Hayman
Journal:  Curr Treat Options Oncol       Date:  2005-05

4.  WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

Authors:  Eleanor M Tyler; Achim A Jungbluth; Richard J O'Reilly; Guenther Koehne
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

5.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

6.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.

Authors:  W A Erik Marijt; Mirjam H M Heemskerk; Freke M Kloosterboer; Els Goulmy; Michel G D Kester; Menno A W G van der Hoorn; Simone A P van Luxemburg-Heys; Manja Hoogeboom; Tuna Mutis; Jan Wouter Drijfhout; Jon J van Rood; Roel Willemze; J H Frederik Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-24       Impact factor: 11.205

Review 7.  Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

Authors:  Rebecca Karp Leaf; Hearn Jay Cho; David Avigan
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 8.  Breakthroughs in the management of multiple myeloma.

Authors:  Leonard T Heffner; Sagar Lonial
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.